AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04572932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactobacillus delbruekii
Description: Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl
Study NCT01649661 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Study NCT04556695 — intervention group
Intervention type: OTHER
Intervention: Questionnaire survey
Description: Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)
Study NCT04556695 — intervention group
Intervention type: DEVICE
Intervention: Accelerometer study
Description: Consenting participants will be asked to wear an accelerometer on the lateral aspect of the middle of the right thigh (over the midpoint of the iliotibial band), continuously over a seven-day period.
Study NCT04556695 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interview study
Description: Semi-structured interviews will take place via telephone or webcam. Participants will be given feedback regarding their accelerometer data relating to their levels of physical activity and sedentary behaviour. Questions will examine participants' thoughts and opinions regarding sedentary behaviour and physical activity in the General Practice setting. Further questions will explore participants' experiences of wearing accelerometers, their knowledge of and attitudes towards physical activity and sedentary behaviour and their thoughts or suggestions on interventions to reduce sedentary behaviour among GPs and GPSTs.
Study NCT02769455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference intakes
Description: FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.~The presentation of the products will always include the label affixed on it. Moreover, the product pages will include two pictures of the product: one with only the package (including the RI as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant. These elements ensure higher visibility, awareness and understanding of the label.
Study NCT02769455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-CNL
Description: The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format includes five categories, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the one corresponding to the product being enlarged.~The presentation of the products will always include the label affixed on it. Two pictures of the product will be included: one with only the package (including the 5-CNL as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant.
Study NCT02837575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCL-HB01
Description: Investigational Product
Study NCT02837575 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate-buffered saline
Description: Placebo
Study NCT03608592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord derived mesenchymal stem cells (UCMSCs) suspension
Description: Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours.
Study NCT03608592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: normal saline
Description: A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.
Study NCT02356068 — intervention group
Intervention type: OTHER
Intervention: ROTEM analysis
Description: 3 blood samples for ROTEM analysis
Study NCT01931852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Participants in the CMR-guided care group will receive a cardiac MRI.
Study NCT02289118 — intervention group
Intervention type: DRUG
Intervention: [18F]-T807 imaging tracer
Description: Tau Imaging tracer
Study NCT01931852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACC/AHA Guideline adherent care
Description: Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations. ( ACC/AHA Guideline adherent care )
Study NCT03659812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MACS technique
Description: MACS is a technique that allow us to tag and detect apoptotic spermatozoa. These apoptotic spermatozoa have phosphatidylserine in their membranes, so we add magnetic beads with Annexin V, which binds specifically to phosphatidylserine. The spermatozoa are then tagged and can be retained in a magnetic field, allowing us to collect just the non-apoptotic spermatozoa.
Study NCT01382823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser
Description: Using the Femtosecond Laser to make a clear corneal incision.
Study NCT02611557 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manual lymphatic drainage therapy
Description: Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
Study NCT03922711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: Oral capsule
Study NCT03922711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT03922711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral capsule
Study NCT05229575 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT
Study NCT03310021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Description: fXa inhibitor antidote
Study NCT03310021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: factor Xa inhibitor
Study NCT03310021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: factor Xa inhibitor
Study NCT03310021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: factor Xa inhibitor
Study NCT03310021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02231723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: Administered continuously twice daily with doses separated by 12 hours
Study NCT02231723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 125 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
Study NCT02231723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
Study NCT02231723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
Study NCT02231723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Arm C, D: Leucovorin 400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
Study NCT02231723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Arm B: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
Study NCT00612209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: Treatment with ARQ 197
Study NCT02231723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Arm B, D: Fluorouracil 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m\^2 I.V. bolus followed by 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
Study NCT02231723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398
Description: MM-398 70 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
Study NCT01233440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor IX Albumin Fusion Protein
Description: Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion
Study NCT01233440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma derived FIX [pdFIX]
Description: Single dose of 50 IU/kg of reference product, given as intravenous infusion
Study NCT04006574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Core stabilization
Study NCT04006574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Core stabilization
Study NCT04675645 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HU-Go app
Description: A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
Study NCT03648268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation
Study NCT03870893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hippotherapy
Description: 16weeks hippotherapy program
Study NCT04547491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPI - hypotension prediction index
Description: treatment of hypotension before the appearance following HPI algorithm
Study NCT04547491 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GDT
Description: cardiac optimization and treatment of hypotension following standard clinical practice
Study NCT00826540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00826540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT04372979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transfusion of SARS-CoV-2 Convalescent Plasma.
Description: 2 Convalescent Plasma units of 200-230mL each, inactivated by amotosalen.
Study NCT03648268 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation
Study NCT00582972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 mg po qAM one-half hour before breakfast for 30 days
Study NCT02564705 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior Lumbar Interbody Fusion (ALIF)
Study NCT02564705 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior Fusion
Description: * Posterolateral Fusion (PLF)~* Posterior Lumbar Interbody Fusion (PLIF)~* Transforaminal Lumbar Interbody Fusion (TLIF)
Study NCT01940107 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: evaluations
Description: Only evaluations
Study NCT01940107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocol of physiotherapy exercises
Description: Oriented domiciliary physiotherapeutic exercises
Study NCT02551237 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 50 Gy
Description: radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
Study NCT02551237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
Study NCT02551237 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 25 Gy
Description: radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
Study NCT02423642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy with regional citrate anticoagulation
Description: CRRT with anticoagulant : regional citrate anticoagulation~Filter : AQUAMAX™ (Edwards Lifesciences)
Study NCT02423642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy with no anticoagulation or heparin
Description: CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
Study NCT02144597 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liquid formula low-calorie diet (LCD)
Description: The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.
Study NCT02144597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Description: Participant went through Roux-en-Y gastric bypass (RYGB) surgery
Study NCT02144597 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y gastric bypass (RYGB)
Description: Participant went through Roux-en-Y gastric bypass (RYGB) surgery
Study NCT02144597 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control diet
Study NCT04372979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion of standard Plasma.
Description: 2 Standard Plasma units of 200-230mL each, inactivated by amotosalen.
Study NCT05265585 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound - Cardiac Acquisition
Description: The evaluation of the algorithm takes place on patients with an indication for echocardiography.~This examination is done in a standard way with the potential specific explorations related to the indication of the examination. During the echocardiography, the operator records the search phase for the following reference views:~* Parasternal window (Parasternal long axis, Parasternal minor axis)~* Apical window (Apical 4 cavities, Apical 3 cavities, Apical 2 cavities~* Sub costal window, Sub costal 4 cavities, Inferior vena cava)
Study NCT03623204 — intervention group
Intervention type: OTHER
Intervention: Dyspnea evaluation
Study NCT02709941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle strength training
Description: Breathing training designed to augment inspiratory muscle strength, and thus targeted muscle groups may benefit from improved force generating capability result in improved breathing.
Study NCT02709941 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02689141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
Study NCT02689141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v.
Study NCT01116154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT01116154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT01116154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03668912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided participation discharge programme
Description: A nurse-led GP discharge intervention (3 structured 30- to 60-minute GP sessions and 1 follow-up phone call)
Study NCT01804465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SipT Treatment
Description: All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion.
Study NCT01804465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
Study NCT00524784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ApoCell
Description: Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
Study NCT02152033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Continuing Care
Description: All sessions will occur over the phone or Cisco WebEx meetings. Parents will participate in 5 individual sessions and 1 joint session with their child (45-50 min. each). Young Adults (YAs) will participate in 1-3 individual meetings (30- 45 min. each) and 1 joint session (45-50 min.). In addition, YAs will be contacted weekly for the first 8 weeks of HCC, then every other week for the remaining 24 weeks (20 calls total). He or she will be asked questions addressing risk and protective factors for relapse. Finally, parents will be trained to collect and test their child's urine sample and deliver incentives to the YA contingent upon biologically-verified abstinence and verified engagement in continuing service plan activities. Urine samples will be collected regularly over a 32 week period.
Study NCT02152033 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Services as Usual
Description: Young Adults (YAs) will be told to follow the continuing service plan recommended by the residential treatment program. Parents will be told to support this and be sent information on continuing care developed by the Treatment Research Institute and the Partnership @ Drugfree.org (http://continuingcare.drugfree.org). We will provide no supplemental services during the study. We will train parents; however, on how to collect urine samples for research purposes only. They will not be trained on how to test the urine sample, only how to collect it and mail the sample to our staff for testing. We will offer separate 4 hour-workshops to parents and YAs after they have completed participation as an added study participation incentive for this group.
Study NCT03928600 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cervical Foley combined with Misoprostol
Description: Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug
Study NCT01922440 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a non-interventional study.
Study NCT03928600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dinoprostone 10mg insert OR
Description: Application for 24h of Dinoprostone 10mg insert
Study NCT03928600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Application of vaginal misoprostol 25ug 4/4h until 150ug
Study NCT03926169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risankizumab
Description: Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
Study NCT03926169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
Study NCT03926169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for risankizumab
Description: Placebo for risankizumab is administered as a SC injection in PFS